33 / 37
EVEROLIMUS IS CLINICALLY BENEFICIAL REGARDLESS
OF PRIOR CHEMOTHERAPY USE
Lombard-Bohas C, et al.
J Clin Oncol.
2012; 30 suppl. 34; abstract # 224.
p value is obtained from the unstratified one-sided log-rank test. Hazard ratio is obtained from unstratified unadjusted Cox model.
In the everolimus arm, median PFS did not significantly differ in patients who did and did not receive prior chemotherapy
In the placebo arm, a trend toward shorter median PFS was observed in patients who had received prior chemotherapy compared
with chemo-naive patients